ADMA Biologics (NASDAQ:ADMA) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.02), Fidelity Earnings reports. The firm had revenue of $4.23 million during the quarter, compared to the consensus estimate of $5.39 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%.
Shares of ADMA opened at $5.26 on Friday. The company has a current ratio of 10.65, a quick ratio of 8.88 and a debt-to-equity ratio of 0.79. ADMA Biologics has a 1 year low of $2.10 and a 1 year high of $6.96. The stock has a market cap of $266.97 million, a price-to-earnings ratio of -2.75 and a beta of 2.28.
A hedge fund recently raised its stake in ADMA Biologics stock. Bank of New York Mellon Corp grew its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 188.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,828 shares of the biotechnology company’s stock after buying an additional 35,791 shares during the period. Bank of New York Mellon Corp owned approximately 0.12% of ADMA Biologics worth $247,000 as of its most recent filing with the Securities and Exchange Commission. 55.07% of the stock is currently owned by institutional investors.
Several equities analysts recently issued reports on the company. HC Wainwright set a $17.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Friday. ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. Oppenheimer set a $13.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Sunday, August 5th. Maxim Group raised their price target on ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, July 26th. Finally, BidaskClub cut ADMA Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Eight investment analysts have rated the stock with a buy rating, ADMA Biologics currently has an average rating of “Buy” and a consensus target price of $11.58.
TRADEMARK VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/11/10/adma-biologics-adma-issues-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Read More: How analysts view the yield curve
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.